{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:00:55Z","timestamp":1787022055393,"version":"build-2736575974"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Relypsa, Inc., a Vifor Pharma Group Company"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226844","type":"journal-article","created":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T13:37:49Z","timestamp":1578404269000},"page":"e0226844","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2384-2545","authenticated-orcid":true,"given":"Nihar R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanene","family":"Fogli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"issue":"12","key":"pone.0226844.ref001","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"LM Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"pone.0226844.ref002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ekir.2018.10.020","article-title":"Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients","volume":"4","author":"CP Kovesdy","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"1","key":"pone.0226844.ref003","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ekir.2016.03.001","article-title":"The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials","volume":"1","author":"M Epstein","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"6","key":"pone.0226844.ref004","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of Potassium Homeostasis","volume":"10","author":"B Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"pone.0226844.ref005","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrneph.2014.168","article-title":"Management of hyperkalaemia in chronic kidney disease","volume":"10","author":"CP Kovesdy","year":"2014","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"pone.0226844.ref006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease","volume":"34","author":"L Lazich","year":"2014","journal-title":"Semin Nephrol"},{"issue":"8","key":"pone.0226844.ref007","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","article-title":"Prevalence and Factors Associated with Hyperkalemia in Predialysis Patients Followed in a Low-Clearance Clinic","volume":"7","author":"PA Sarafidis","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"pone.0226844.ref008","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","article-title":"Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease","volume":"109","author":"N Jain","year":"2012","journal-title":"Am J Cardiol"},{"key":"pone.0226844.ref009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"BF Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0226844.ref010","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"NM Albert","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"pone.0226844.ref011","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"EJ Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0226844.ref012","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0226844.ref013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease\u2014A meta-analysis of patient-level data","volume":"135","author":"TH Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"21","key":"pone.0226844.ref014","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis\u2014A randomized controlled trial","volume":"285","author":"LY Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"23","key":"pone.0226844.ref015","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive-heart-failure-results of the Cooperative-North-Scandinavian-Enalapril-Survival-Study (CONSENSUS)","volume":"316","author":"CTS Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0226844.ref016","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"S11","key":"pone.0226844.ref017","first-page":"S313","article-title":"Evaluation of clinical outocmes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors","volume":"22","author":"M Epstein","year":"2016","journal-title":"Am J Manag Care"},{"issue":"24","key":"pone.0226844.ref018","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"W Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0226844.ref019","first-page":"43","article-title":"Potassium-Binding Agents for the Clinical Management of Hyperkalemia","volume":"41","author":"M Chaitman","year":"2016","journal-title":"P & T: a peer-reviewed journal for formulary management"},{"key":"pone.0226844.ref020","unstructured":"Veltassa\u00ae (patiromer) for oral suspension [package insert]. Redwood City CR, Inc. 2018."},{"issue":"5","key":"pone.0226844.ref021","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1074248416629549","article-title":"Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia","volume":"21","author":"L Li","year":"2016","journal-title":"Journal of cardiovascular pharmacology and therapeutics"},{"issue":"10","key":"pone.0226844.ref022","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"B Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"pone.0226844.ref023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"MR Weir","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0226844.ref024","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial","volume":"314","author":"GL Bakris","year":"2015","journal-title":"JAMA-J Am Med Assoc"},{"issue":"9","key":"pone.0226844.ref025","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3\u20135 in clinical practice: a safety concern?","volume":"34","author":"T AM Yildirim","year":"2012","journal-title":"Ren Fail"},{"issue":"2","key":"pone.0226844.ref026","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","article-title":"The Cost of Hyperkalemia in the United States","volume":"3","author":"KA Betts","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"3","key":"pone.0226844.ref027","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/aje\/kwv446","article-title":"Validity of Self-Reported Medication Use Compared With Pharmacy Records in a Cohort of Older Women: Findings From the Women's Health Initiative","volume":"184","author":"RL Drieling","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pone.0226844.ref028","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jclinepi.2013.02.016","article-title":"Agreement between patient interview data on prescription medication use and pharmacy records in those aged older than 50 years varied by therapeutic group and reporting of indicated health conditions","volume":"66","author":"K Richardson","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"pone.0226844.ref029","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.mlr.0000207817.32496.cb","article-title":"Validity of a prescription claims database to estimate medication adherence in older persons","volume":"44","author":"R Grymonpre","year":"2006","journal-title":"Med Care"},{"issue":"10","key":"pone.0226844.ref030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/pds.1226","article-title":"Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users","volume":"15","author":"JR Curtis","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"pone.0226844.ref031","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1345\/aph.10379","article-title":"Compliance from self-reported versus pharmacy claims data with metered-dose inhalers","volume":"35","author":"SR Erickson","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0226844.ref032","first-page":"78","article-title":"Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults","volume":"43","author":"JB Nachega","year":"2006","journal-title":"Jaids"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T13:39:23Z","timestamp":1578404363000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226844"}},"subtitle":[],"editor":[{"given":"Antonio Carlos","family":"Seguro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226844","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]}}}